- —
Venture capital deployed · 2026 YTD
Sector market cap
Largest raise · trailing 12mo
Catalysts ahead · next 12mo
Companies tracked
Nothing on the calendar yet.
Mega-rounds have thinned since 2021, when Commure ($500M), Ro ($500M) and Noom ($540M) led. The past 12 months brought Oura ($900M, Oct 2025) and Whoop ($575M, Mar 2026), but the median disclosed round has settled near $40M to $70M.
Capital is concentrating late. Series E and later rounds dominate the last year: Oura, Whoop, Verily ($300M), Suki ($90M) and Aidoc ($150M). Seed and Series A rounds are scarce, with the newest Series A in the data dating to 2024.
Andreessen Horowitz led Ambience ($243M) and Abridge ($300M), and General Catalyst remains the most active name since 2020. Fidelity led Oura's $900M round. New entrants include Collaborative Fund, Blackbird and Goldman Sachs Alternatives. Tiger Global, Lyra's and Medable's 2021 backer, has not led a round since 2021.
Health tech's regulatory moat is shifting from the model to the update: every retrain or cloud move may reset clearance.
Health tech's scarce asset is no longer model capability but the licensed, accountable human who signs off on it.
Pharma's AI labs are racing to prove efficacy before their capital burn reveals whether automation actually works.
The AI drug-discovery boom is masking a valuation crisis that will force consolidation before any real productivity gains materialize.
As of 2026-08-01